Agenus joins Rodman & Renshaw fireside chat to discuss BOT+BAL development
AGEN•Agenus will join a virtual Rodman & Renshaw fireside chat on Nov. 5, 2026, to discuss botensilimab and balstilimab development, including colon cancer results, a planned Phase 3 trial, strategic priorities, funding and commercial opportunity.
1. Fireside chat topics
Agenus will participate in the virtual fireside chat from 11:30 a.m. to 12:30 p.m. ET on Nov. 5, 2026. Discussion will cover botensilimab and balstilimab development, neoadjuvant colon cancer results, the planned Phase 3 ROBBIN trial, strategic priorities, funding and the combination’s commercial opportunity.
